Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 230

1.

Infection risk in rheumatoid arthritis and spondyloarthropathy patients under treatment with DMARDs, corticosteroids and TNF-α antagonists.

Germano V, Cattaruzza MS, Osborn J, Tarantino A, Di Rosa R, Salemi S, D'Amelio R.

J Transl Med. 2014 Mar 22;12:77. doi: 10.1186/1479-5876-12-77.

2.

Risk of Subsequent Infection Among Patients Receiving Tumor Necrosis Factor Inhibitors and Other Disease-Modifying Antirheumatic Drugs.

Accortt NA, Bonafede MM, Collier DH, Iles J, Curtis JR.

Arthritis Rheumatol. 2016 Jan;68(1):67-76. doi: 10.1002/art.39416.

3.

Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register.

Harrison MJ, Dixon WG, Watson KD, King Y, Groves R, Hyrich KL, Symmons DP; British Society for Rheumatology Biologics Register Control Centre Consortium; BSRBR.

Ann Rheum Dis. 2009 Feb;68(2):209-15. doi: 10.1136/ard.2007.087288. Epub 2008 Apr 2.

4.

Rheumatoid arthritis and the incidence of influenza and influenza-related complications: a retrospective cohort study.

Blumentals WA, Arreglado A, Napalkov P, Toovey S.

BMC Musculoskelet Disord. 2012 Aug 27;13:158. doi: 10.1186/1471-2474-13-158.

5.

TNF blockers show distinct patterns of immune response to the pandemic influenza A H1N1 vaccine in inflammatory arthritis patients.

França IL, Ribeiro AC, Aikawa NE, Saad CG, Moraes JC, Goldstein-Schainberg C, Laurindo IM, Precioso AR, Ishida MA, Sartori AM, Silva CA, Bonfa E.

Rheumatology (Oxford). 2012 Nov;51(11):2091-8. doi: 10.1093/rheumatology/kes202. Epub 2012 Aug 20.

PMID:
22908326
6.

Biologic treatment for rheumatic disease: real-world big data analysis from the Greek country-wide prescription database.

Sfikakis PP, Bournia VK, Sidiropoulos P, Boumpas DT, Drosos AA, Kitas GD, Konstantonis G, Liossis SN, Manoussakis MN, Sakkas L, Tektonidou M, Tzioufas AG, Vlachoyiannopoulos PG, Kani C, Paterakis P, Litsa P, Vassilopoulos D.

Clin Exp Rheumatol. 2017 Jul-Aug;35(4):579-585. Epub 2017 Mar 3.

PMID:
28281458
7.

Use of nonbiologic disease-modifying antirheumatic drugs and risk of infection in patients with rheumatoid arthritis.

Lacaille D, Guh DP, Abrahamowicz M, Anis AH, Esdaile JM.

Arthritis Rheum. 2008 Aug 15;59(8):1074-81. doi: 10.1002/art.23913.

8.

Anti-tumor necrosis factor alpha therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis.

Schneeweiss S, Setoguchi S, Weinblatt ME, Katz JN, Avorn J, Sax PE, Levin R, Solomon DH.

Arthritis Rheum. 2007 Jun;56(6):1754-64.

9.

Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient?

Strangfeld A, Eveslage M, Schneider M, Bergerhausen HJ, Klopsch T, Zink A, Listing J.

Ann Rheum Dis. 2011 Nov;70(11):1914-20. doi: 10.1136/ard.2011.151043. Epub 2011 Jul 25.

10.
11.

Lack of adverse effect of anti-tumor necrosis factor-α biologics in treatment of rheumatoid arthritis: 5 years follow-up.

Dewedar AM, Shalaby MA, Al-Homaid S, Mahfouz AM, Shams OA, Fathy A.

Int J Rheum Dis. 2012 Jun;15(3):330-5. doi: 10.1111/j.1756-185X.2012.01715.x. Epub 2012 Feb 13.

PMID:
22709496
12.

Incidence and risk factors for serious infection in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: a report from the Registry of Japanese Rheumatoid Arthritis Patients for Longterm Safety.

Komano Y, Tanaka M, Nanki T, Koike R, Sakai R, Kameda H, Nakajima A, Saito K, Takeno M, Atsumi T, Tohma S, Ito S, Tamura N, Fujii T, Sawada T, Ida H, Hashiramoto A, Koike T, Ishigatsubo Y, Eguchi K, Tanaka Y, Takeuchi T, Miyasaka N, Harigai M; REAL Study Group.

J Rheumatol. 2011 Jul;38(7):1258-64. doi: 10.3899/jrheum.101009. Epub 2011 Apr 15.

PMID:
21498482
13.
14.

Association between the initiation of anti-tumor necrosis factor therapy and the risk of herpes zoster.

Winthrop KL, Baddley JW, Chen L, Liu L, Grijalva CG, Delzell E, Beukelman T, Patkar NM, Xie F, Saag KG, Herrinton LJ, Solomon DH, Lewis JD, Curtis JR.

JAMA. 2013 Mar 6;309(9):887-95. doi: 10.1001/jama.2013.1099.

15.
16.

Hospitalizations of patients treated with anti-tumor necrosis factor-α agents -- a retrospective cohort analysis.

Zisman D, Haddad A, Hashoul S, Laor A, Bitterman H, Rosner I, Eder L, Balbir-Gurman A, Mader R, Milman U.

J Rheumatol. 2013 Jan;40(1):16-22. doi: 10.3899/jrheum.111516. Epub 2012 Oct 15.

PMID:
23070992
17.

Anti-rheumatic drug use and risk of serious infections in rheumatoid arthritis.

Bernatsky S, Hudson M, Suissa S.

Rheumatology (Oxford). 2007 Jul;46(7):1157-60. Epub 2007 May 3.

PMID:
17478469
18.

Association of methotrexate and tumour necrosis factor antagonists with risk of infectious outcomes including opportunistic infections in the CORRONA registry.

Greenberg JD, Reed G, Kremer JM, Tindall E, Kavanaugh A, Zheng C, Bishai W, Hochberg MC; CORRONA Investigators.

Ann Rheum Dis. 2010 Feb;69(2):380-6. doi: 10.1136/ard.2008.089276. Epub 2009 Apr 8.

19.

Association between disease activity and risk of serious infections in subjects with rheumatoid arthritis treated with etanercept or disease-modifying anti-rheumatic drugs.

Emery P, Gallo G, Boyd H, Morgan CL, Currie CJ, Poole CD, Nab HW.

Clin Exp Rheumatol. 2014 Sep-Oct;32(5):653-60. Epub 2014 Sep 5.

PMID:
25190189
20.

Use of a disease risk score to compare serious infections associated with anti-tumor necrosis factor therapy among high- versus lower-risk rheumatoid arthritis patients.

Curtis JR, Xie F, Chen L, Muntner P, Grijalva CG, Spettell C, Fernandes J, McMahan RM, Baddley JW, Saag KG, Beukelman T, Delzell E.

Arthritis Care Res (Hoboken). 2012 Oct;64(10):1480-9. doi: 10.1002/acr.21805.

Supplemental Content

Support Center